Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Zealand Pharma

< Previous 1 2 3 Next >
Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
From Zealand Pharma
Via GlobeNewswire
SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to participate in upcoming healthcare conferences in September 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Half of 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
From Zealand Pharma
Via GlobeNewswire
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Quarter of 2023
From Zealand Pharma
Via GlobeNewswire
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
From Zealand Pharma
Via GlobeNewswire
Correction: Zealand Pharma convenes its Annual General Meeting 2023
From Zealand Pharma
Via GlobeNewswire
Correction: Zealand Pharma Announces Full Year Results for 2022
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma convenes its Annual General Meeting 2023
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Full Year Results for 2022
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma to Participate in Upcoming Investor Conferences
From Zealand Pharma
Via GlobeNewswire
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
From Zealand Pharma
Via GlobeNewswire
Tickers ZEAL
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
From Zealand Pharma
Via GlobeNewswire
Tickers ZEAL
Zealand Pharma major shareholder announcement: Polar Capital
From Zealand Pharma
Via GlobeNewswire
Tickers ZEAL
Zealand Pharma major shareholder announcement: Van Herk Investments
From Zealand Pharma
Via GlobeNewswire
Tickers ZEAL
Zealand Pharma completes registration of capital increase
From Zealand Pharma
Via GlobeNewswire
Tickers ZEAL
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.